Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)



Status:Recruiting
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:5/23/2018
Start Date:July 17, 2017
End Date:December 2019
Contact:Byron Kaelin, RN, BSHS
Email:bkaelin@cumberlandpharma.com
Phone:615-255-0068

Use our guide to learn which trials are right for you!

A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)

The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for
the treatment of aspirin-exacerbated respiratory disease (AERD). AERD is a disease that
involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other
nonsteroidal anti-inflammatory drugs.

This is a randomized, placebo-controlled, double-blind phase 2 trial evaluating approximately
76 subjects with symptomatic AERD on the safety and efficacy of 8 weeks of oral ifetroban
treatment. Eligible AERD subjects will be randomized to receive 8 weeks of either oral
ifetroban daily or matching placebo followed by a 2-week post-treatment period.

Inclusion Criteria:

1. History of physician-diagnosed asthma

2. History of nasal polyposis

3. History of at least two reactions to oral aspirin or other nonselective cyclooxygenase
inhibitor with features of lower airway involvement (cough, chest tightness, wheezing,
dyspnea), or one reaction that was life-threatening and required hospitalization, or a
diagnosis of AERD by a physician-conducted challenge to aspirin in the last five years
before starting treatment.

4. Stable asthma (post-bronchodilator FEV1 of ≥ 60%, no glucocorticoid burst for at least
two weeks prior to starting treatment, no hospitalizations or emergency room visits
for asthma at least three months prior to starting treatment and not on a dose >1000
µg fluticasone or equivalent daily).

5. ≥ 18 years of age

6. Exhibit symptomatic AERD within three weeks of starting treatment by demonstrating a
score of at least 20 on the Sino-nasal Outcome Test (SNOT) - 22.

Exclusion Criteria:

1. Current smoking, defined as daily tobacco smoking in the last six months and at least
one instance of tobacco smoking in the last three months.

2. Current pregnancy or breastfeeding

3. Use of oral or systemic steroids (e.g. prednisone or equivalent) > 20 mg daily in the
last four weeks before starting treatment.

4. Daily use of long-acting antihistamines in the last two weeks before starting
treatment.

5. Less than 12 months of allergy shots (maintenance dose of allergy shots are allowed if
treatment duration exceeds 12 months). Less than 1 month of 5-lipoxygenase inhibitors
(e.g. zileuton) and/or leukotriene receptor antagonists (e.g. montelukast).

6. Any use of nonsteroidal anti-inflammatory drugs (NSAIDs) or any drug that inhibits the
cyclooxygenase enzyme in the last two weeks before starting treatment.

7. History of bleeding diathesis or use of anticoagulant or antiplatelet drugs in the
last two weeks before starting treatment.

8. Any immunosuppressive treatment including but not limited to methotrexate,
cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine,
hydroxychloroquine, azathioprine, and cyclophosphamide in the last two weeks before
starting treatment (maintenance dose of allergy shots are allowed if treatment
duration exceeds 12 months). Biologics/immunotherapies such as Xolair or Nucala are
permitted if duration exceeds three months.

9. Endoscopic sinus surgery / polypectomy within the past three months

10. Previously treated in a clinical trial with ifetroban within the past three months.

11. Previously treated with other investigational drugs within eight weeks or five
half-lives, whichever is longer, before screening

12. Conditions/concomitant disease which make them unevaluable for the efficacy endpoints
We found this trial at
10
sites
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Principal Investigator: Elina Jerschow, MD
Phone: 929-263-3262
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Rakesh Chandra, MD
Phone: 615-936-8384
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
8675 College Boulevard
Overland Park, Kansas 66210
913-345-2383
Phone: 913-338-1610
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
4825 Higbee Avenue Northwest
Canton, Ohio 44718
Phone: 330-492-3345
?
mi
from
Canton, OH
Click here to add this to my saved trials
Charlottesville, Virginia 22908
Principal Investigator: Spencer Payne, MD
Phone: 434-243-1558
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: David Khan, MD
Phone: 214-648-3626
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Hialeah, Florida 33016
Phone: 305-603-8844
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
San Diego, California 92130
Principal Investigator: Andrew White, MD
Phone: 858-764-3023
?
mi
from
San Diego, CA
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Principal Investigator: Peter Hwang, MD
Phone: 408-872-2257
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
?
mi
from
Stanford, CA
Click here to add this to my saved trials